Scholar Rock resubmits Apitegromab BLA to FDA, shares rise
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 hours ago
0mins
Should l Buy SRRK?
Source: Newsfilter
Scholar Rock Holding Corp's shares surged by 15.30% as the company reached a 20-day high.
The significant price movement follows Scholar Rock's announcement of the resubmission of its Biologics License Application (BLA) for Apitegromab to the FDA, with expectations for acceptance within 30 days and a review period of up to six months. This resubmission includes plans for a second U.S.-based fill-finish facility to enhance the supply chain for Apitegromab, which is aimed at treating spinal muscular atrophy (SMA). The company has also reported positive interactions with the FDA, indicating a strong likelihood of approval.
This development not only boosts Scholar Rock's competitive position in the market but also lays the groundwork for future commercialization of Apitegromab, which could significantly impact SMA patients globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRRK
Wall Street analysts forecast SRRK stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 43.080
Low
42.00
Averages
50.00
High
60.00
Current: 43.080
Low
42.00
Averages
50.00
High
60.00
About SRRK
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scholar Rock Resubmits Apitegromab BLA to FDA
- BLA Resubmission: Scholar Rock has resubmitted the Biologics License Application (BLA) for Apitegromab to the FDA, anticipating acceptance within 30 days and a review period of up to six months, which could provide new treatment options for SMA patients.
- Facility Expansion: The resubmission includes a second U.S.-based fill-finish facility aimed at strengthening the supply chain for Apitegromab to meet growing market demand, thereby enhancing the company's competitive position globally.
- Positive FDA Interactions: Scholar Rock's frequent and constructive interactions with the FDA, particularly during the Q1 2026 meeting, have led to alignment on the resubmission process, indicating the FDA's commitment to the drug's approval.
- European Market Progress: The review of the Marketing Authorisation Application (MAA) for Apitegromab in Europe is progressing well, with a decision expected in mid-2026, further supporting the company's global business expansion.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
Scholar Rock Revises Q4 and Full Year 2025 Financial Results
- Financial Loss Revision: Scholar Rock reported a net loss of $91 million for Q4 2025, translating to a loss per share of $0.76, compared to $66.5 million and $0.61 in Q4 2024, indicating ongoing financial strain that may impact investor confidence.
- Annual Loss Increase: The total net loss for 2025 reached $377.9 million, significantly up from $246.3 million in 2024, reflecting high R&D and operational expenditures that could challenge future financing capabilities.
- FDA Review Progress: The CEO noted that the FDA's review of apitegromab is progressing well, with plans to resubmit the BLA following successful reinspection, which could open new market opportunities and enhance the company's competitiveness in SMA treatment.
- Future Outlook: Scholar Rock anticipates 2026 to be a transformative year; despite financial challenges, the company is aggressively advancing its pipeline, demonstrating confidence in future growth that may attract long-term investor interest.
See More
Scholar Rock Q4 Earnings Beat Expectations Despite No Revenue
- Earnings Performance: Scholar Rock reported a GAAP EPS of -$0.88 for Q4 2025, beating expectations by $0.01, despite recording no revenue for both Q4 2025 and 2024, indicating ongoing financial challenges.
- Cash Reserves: As of December 31, 2025, Scholar Rock had cash, cash equivalents, and marketable securities totaling $367.6 million, which includes $60.4 million from the exercise of outstanding warrants, providing some financial cushion for future operations.
- Market Response: Despite the lack of revenue, Scholar Rock presented the prospects of its product Apitegromab at the J.P. Morgan Healthcare Conference, maintaining a buy rating, which reflects market confidence in its long-term potential.
- Historical Performance: Historical earnings data for Scholar Rock indicates that the company has faced ongoing revenue challenges over recent quarters, necessitating improvements through product development and market outreach to enhance financial performance.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation
- Share Acquisition: Redmile Group disclosed a purchase of 1,316,390 shares of Scholar Rock Holding Corporation in an SEC filing dated February 17, 2026, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, highlighting its significance in the fund's asset management and reinforcing its investment strategy in the biopharmaceutical sector.
- Market Performance: As of February 17, 2026, Scholar Rock's shares were priced at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, suggesting positive market expectations regarding its product development.
- Financial Position: Scholar Rock has a market capitalization of $4.78 billion, and while it reported a net income of -$353.43 million, its cash reserves of approximately $365 million provide a buffer for future growth, reducing near-term dilution risk and attracting long-term investors.
See More
Scholar Rock Resubmits Apitegromab BLA to FDA
- BLA Resubmission: Scholar Rock has resubmitted the Biologics License Application (BLA) for Apitegromab to the FDA, anticipating acceptance within 30 days and a review period of up to six months, which could provide new treatment options for SMA patients.
- Facility Expansion: The resubmission includes a second U.S.-based fill-finish facility aimed at strengthening the supply chain for Apitegromab to meet growing market demand, thereby enhancing the company's competitive position globally.
- Positive FDA Interactions: Scholar Rock's frequent and constructive interactions with the FDA, particularly during the Q1 2026 meeting, have led to alignment on the resubmission process, indicating the FDA's commitment to the drug's approval.
- European Market Progress: The review of the Marketing Authorisation Application (MAA) for Apitegromab in Europe is progressing well, with a decision expected in mid-2026, further supporting the company's global business expansion.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
US Stocks Surge as Market Sentiment Improves
- Market Rebound: The S&P 500 Index rose by 1.33%, the Dow Jones Industrial Average increased by 1.10%, and the Nasdaq 100 Index climbed by 1.45%, reflecting investor optimism following President Trump's willingness to end military actions against Iran, potentially easing geopolitical tensions.
- Supportive Economic Data: China's March manufacturing PMI rose by 1.4 to 50.4, surpassing expectations of 50.1, indicating signs of economic recovery that could enhance global growth prospects and drive stock markets higher.
- Falling Bond Yields: The 10-year T-note yield dropped to 4.30%, a one-week low, as WTI crude oil prices fell, alleviating inflation concerns and lowering borrowing costs, thereby supporting further gains in the stock market.
- Tech Stocks Lead Gains: The
See More
Scholar Rock Revises Q4 and Full Year 2025 Financial Results
- Financial Loss Revision: Scholar Rock reported a net loss of $91 million for Q4 2025, translating to a loss per share of $0.76, compared to $66.5 million and $0.61 in Q4 2024, indicating ongoing financial strain that may impact investor confidence.
- Annual Loss Increase: The total net loss for 2025 reached $377.9 million, significantly up from $246.3 million in 2024, reflecting high R&D and operational expenditures that could challenge future financing capabilities.
- FDA Review Progress: The CEO noted that the FDA's review of apitegromab is progressing well, with plans to resubmit the BLA following successful reinspection, which could open new market opportunities and enhance the company's competitiveness in SMA treatment.
- Future Outlook: Scholar Rock anticipates 2026 to be a transformative year; despite financial challenges, the company is aggressively advancing its pipeline, demonstrating confidence in future growth that may attract long-term investor interest.
See More
Scholar Rock Q4 Earnings Beat Expectations Despite No Revenue
- Earnings Performance: Scholar Rock reported a GAAP EPS of -$0.88 for Q4 2025, beating expectations by $0.01, despite recording no revenue for both Q4 2025 and 2024, indicating ongoing financial challenges.
- Cash Reserves: As of December 31, 2025, Scholar Rock had cash, cash equivalents, and marketable securities totaling $367.6 million, which includes $60.4 million from the exercise of outstanding warrants, providing some financial cushion for future operations.
- Market Response: Despite the lack of revenue, Scholar Rock presented the prospects of its product Apitegromab at the J.P. Morgan Healthcare Conference, maintaining a buy rating, which reflects market confidence in its long-term potential.
- Historical Performance: Historical earnings data for Scholar Rock indicates that the company has faced ongoing revenue challenges over recent quarters, necessitating improvements through product development and market outreach to enhance financial performance.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation
- Share Acquisition: Redmile Group disclosed a purchase of 1,316,390 shares of Scholar Rock Holding Corporation in an SEC filing dated February 17, 2026, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, highlighting its significance in the fund's asset management and reinforcing its investment strategy in the biopharmaceutical sector.
- Market Performance: As of February 17, 2026, Scholar Rock's shares were priced at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, suggesting positive market expectations regarding its product development.
- Financial Position: Scholar Rock has a market capitalization of $4.78 billion, and while it reported a net income of -$353.43 million, its cash reserves of approximately $365 million provide a buffer for future growth, reducing near-term dilution risk and attracting long-term investors.
See More
